Przejdź do treści

Filtry

Dane naukowe

Podręcznik/instrukcje

Aktualności

Pergolide versus bromocriptine for levodopa-induced complications in Parkinson's disease

Także dostęne w

Wprowadzenie

Long-term levodopa therapy in Parkinson's disease is associated with the development of motor complications including abnormal involuntary movements and a shortening response to each dose (wearing off phenomenon). It is thought that dopamine agonists can reduce the duration of immobile off periods and the need for levodopa therapy whilst maintaining or improving motor impairments and only minimally increasing dopaminergic adverse events.

Cele

To compare the efficacy and safety of adjunct pergolide therapy versus bromocriptine in patients with Parkinson's disease, already established on levodopa and suffering the long-term complications of therapy.

Metody wyszukiwania badań

Electronic searches of MEDLINE, EMBASE and the Cochrane Controlled Trials Register. Handsearching of the neurology literature as part of the Cochrane Movement Disorders Group's strategy. Examination of the reference lists of identified studies and other reviews. Contact with Eli Lilly Company and Sandoz Limited.

Kryteria doboru badań

Randomised controlled trials of pergolide versus bromocriptine in patients with a clinical diagnosis of idiopathic Parkinson's disease and long-term complications of levodopa therapy.

Zbieranie i analiza danych

Data was abstracted independently by each author and differences settled by discussion.

Główne wyniki

Three short-term trials fulfilled the inclusion criteria for the review. Pergolide was superior to bromocriptine regarding UPDRS and NYPDS motor and NYPDS ADL scores in two trials. More patients recorded a 'marked' or 'moderate improvement' in clinician's global impression score with pergolide than bromocriptine in two studies. Insufficient evidence on fluctuations and dyskinesia was available to draw any conclusions. No significant differences between the agonists were seen in levodopa dose reduction, drop outs or adverse events.

Wnioski autorów

Although pergolide is superior to bromocriptine in reducing motor impairments and disability, no firm conclusions regarding levodopa-induced motor complications can be reached. Levodopa dose reduction, adverse events and withdrawals from treatment are similar for the two agonists. The small advantage of pergolide in efficacy does not take into account its additional cost compared with bromocriptine.

Cytowanie
Clarke CE, Speller J. Pergolide versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database of Systematic Reviews 2001, Issue 4. Art. No.: CD000236. DOI: 10.1002/14651858.CD000236.

Używamy plików cookie

Używamy niezbędnych plików cookie, aby nasza strona mogła działać. Chcielibyśmy również ustawić opcjonalne pliki cookie do analizy, aby pomóc nam udoskonalić tę stronę. Nie będziemy ustawiać opcjonalnych plików cookie, chyba że je włączysz. Użycie tego narzędzia spowoduje ustawienie pliku cookie na Twoim urządzeniu, aby zapamiętać Twoje preferencje. W każdej chwili możesz zmienić swoje preferencje dotyczące plików cookie, klikając na link "Ustawienia plików cookie" znajdujący się w stopce każdej strony.
Bardziej szczegółowe informacje na temat używanych przez nas plików cookie można znaleźć na naszej stronieStrona plików cookies

Zaakceptuj wszystkie
Skonfiguruj